Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
The invention relates to mRNA therapy for the treatment of cystic fibrosis. mRNAs for use in the invention, when administered in vivo, encode cystic fibrosis transmembrane conductance regulator (CFTR), isoforms thereof, functional fragments thereof, and fusion proteins comprising CFTR. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of CFTR expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient CFTR activity in subjects.
1. A pharmaceutical composition comprising a lipid nanoparticle, wherein the lipid nanoparticle comprises a compound selected from the group consisting of
or salts and stereoisomers thereof,
wherein the lipid nanoparticle comprises an mRNA that comprises an open reading frame (ORF) encoding a cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide.
2. The pharmaceutical composition of claim 1 , wherein the lipid nanoparticle further comprises a phospholipid.
3. The pharmaceutical composition of claim 1 , wherein the lipid nanoparticle further comprises a structural lipid.
4. The pharmaceutical composition of claim 1 , wherein the lipid nanoparticle further comprises a polyethylene glycol lipid.
5. The pharmaceutical composition of claim 1 , wherein the lipid nanoparticle further comprises a phospholipid, a structural lipid, and a polyethylene glycol lipid.
6. The pharmaceutical composition of claim 2 , wherein the phospholipid is selected from the group consisting of:
1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),
1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),
1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),
1,2-dilinolenoyl-sn-glycero-3-phosphocholine,
1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),
1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16:0 PE),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,
1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,
1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), and sphingomyelin.
7. The pharmaceutical composition of claim 3 , wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, and alpha-tocopherol.
8. The pharmaceutical composition of claim 4 , wherein the polyethylene glycol lipid is selected from the group consisting of a polyethylene glycol-modified phosphatidylethanolamine, a polyethylene glycol-modified phosphatidic acid, a polyethylene glycol-modified ceramide, a polyethylene glycol-modified dialkylamine, a polyethylene glycol-modified diacylglycerol, and a polyethylene glycol-modified dialkylglycerol.
9. The pharmaceutical composition of claim 5 , wherein:
(i) the phospholipid is selected from the group consisting of
1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),
1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),
1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),
1,2-dilinolenoyl-sn-glycero-3-phosphocholine,
1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),
1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16:0 PE),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,
1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,
1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), and sphingomyelin;
(ii) the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, and alpha-tocopherol; and
(iii) the polyethylene glycol lipid is selected from the group consisting of a polyethylene glycol-modified phosphatidylethanolamine, a polyethylene glycol-modified phosphatidic acid, a polyethylene glycol-modified ceramide, a polyethylene glycol-modified dialkylamine, a polyethylene glycol-modified diacylglycerol, and a polyethylene glycol-modified dialkylglycerol.
10. A method of expressing a CFTR polypeptide in a human subject that has cystic fibrosis comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 1 .
11. A method of treating cystic fibrosis in a human subject in need thereof, comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 1 .
12. A method of improving the measure of at least one respiratory volume in a human subject that has cystic fibrosis, comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 1 .
13. The method of claim 12 , wherein the at least one respiratory volume is selected from the group consisting of tidal volume, inspiratory reserve volume, expiratory reserve volume, residual volume, vital capacity, and total lung capacity.
14. A method of reducing sweat gland secretion of chloride in a human subject that has cystic fibrosis, comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 1 .
15. A method of increasing the pH of airway secretions in a human subject that has cystic fibrosis, comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 1 .
16. A pharmaceutical composition comprising a lipid nanoparticle, wherein the lipid nanoparticle comprises Compound 18,
or a salt thereof,
wherein the lipid nanoparticle comprises an mRNA that comprises an open reading frame (ORF) encoding a cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide.
17. The pharmaceutical composition of claim 16 , wherein the lipid nanoparticle further comprises a phospholipid.
18. The pharmaceutical composition of claim 16 , wherein the lipid nanoparticle further comprises a structural lipid.
19. The pharmaceutical composition of claim 16 , wherein the lipid nanoparticle further comprises a polyethylene glycol lipid.
20. The pharmaceutical composition of claim 16 , wherein the lipid nanoparticle further comprises a phospholipid, a structural lipid, and a polyethylene glycol lipid.
21. The pharmaceutical composition of claim 17 , wherein the phospholipid is selected from the group consisting of
1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),
1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),
1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),
1,2-dilinolenoyl-sn-glycero-3-phosphocholine,
1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),
1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16:0 PE),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,
1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,
1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), and sphingomyelin.
22. The pharmaceutical composition of claim 18 , wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, and alpha-tocopherol.
23. The pharmaceutical composition of claim 19 , wherein the polyethylene glycol lipid is selected from the group consisting of a polyethylene glycol-modified phosphatidylethanolamine, a polyethylene glycol-modified phosphatidic acid, a polyethylene glycol-modified ceramide, a polyethylene glycol-modified dialkylamine, a polyethylene glycol-modified diacylglycerol, and a polyethylene glycol-modified dialkylglycerol.
24. The pharmaceutical composition of claim 20 , wherein:
(i) the phospholipid is selected from the group consisting of
1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),
1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),
1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),
1,2-dilinolenoyl-sn-glycero-3-phosphocholine,
1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),
1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16:0 PE),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,
1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,
1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), and sphingomyelin;
(ii) the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, and alpha-tocopherol; and
(iii) the polyethylene glycol lipid is selected from the group consisting of a polyethylene glycol-modified phosphatidylethanolamine, a polyethylene glycol-modified phosphatidic acid, a polyethylene glycol-modified ceramide, a polyethylene glycol-modified dialkylamine, a polyethylene glycol-modified diacylglycerol, and a polyethylene glycol-modified dialkylglycerol.
25. A method of expressing a CFTR polypeptide in a human subject that has cystic fibrosis, comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 16 .
26. A method of treating cystic fibrosis in a human subject in need thereof, comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 16 .
27. A method of improving the measure of at least one respiratory volume in a human subject that has cystic fibrosis, comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 16 .
28. The method of claim 27 , wherein the at least one respiratory volume is selected from the group consisting of tidal volume, inspiratory reserve volume, expiratory reserve volume, residual volume, vital capacity, and total lung capacity.
29. A method of reducing sweat gland secretion of chloride in a human subject that has cystic fibrosis, comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 16 .
30. A method of increasing the pH of airway secretions in a human subject that has cystic fibrosis, comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 16 .